Trial Profile

Phase 1 Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BMS-906024 in Subjects With Advanced Solid Tumours

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 20 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Osugacestat (Primary)
Indications Advanced breast cancer; Colorectal cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Solid tumours; Triple negative breast cancer
Focus Adverse reactions
Sponsors Bristol-Myers Squibb

Most Recent Events

05 Jun 2018 Results (data cut off: 1 Feb, 2018) presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
16 Oct 2017 Status changed from active, no longer recruiting to completed.
15 May 2017 Planned End Date changed from 1 Mar 2017 to 14 Jun 2017.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com